doi.org/10.1016/s0140-6736(21)01324-6

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

Julio Rosenstock

,

,

..., Vivian T. Thieu

The Lancet88.50

Volume: 398, Issue: 10295, Pages: 143 - 155

Published: Jun 27, 2021

Paper Fields

Paper Details

Title

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

DOI

doi.org/10.1016/s0140-6736(21)01324-6

Published Date

Jun 27, 2021

Journal

Volume

398

Issue

10295

Pages

143 - 155

Notes

History